$OLMA News

Olema Oncology Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Olema Pharmaceuticals, Inc. (OLMA) Presents at Morgan Stanley 24th Annual Global Healthcare Conference Transcript

Stifel Maintains Buy on Olema Pharmaceuticals, Lowers Price Target to $30

Olema Pharmaceuticals, Inc. (OLMA) Presents at Citigroup's Biopharma Back to School Summit 2026 Transcript

Olema: Best Breast Cancer Therapy, Or SERD Also-Ran? We'll Find Out In Q1 '27

Olema Oncology Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Olema Oncology to Participate in Upcoming Investor Conferences

JP Morgan Maintains Overweight on Olema Pharmaceuticals, Lowers Price Target to $46

Olema Oncology Appoints Jason O’Byrne as Chief Financial Officer

Citigroup Maintains Buy on Olema Pharmaceuticals, Lowers Price Target to $59

Olema Pharmaceuticals Stock Falls as Pivotal Breast Cancer Data Pushed Into 2027

HC Wainwright & Co. Maintains Buy on Olema Pharmaceuticals, Lowers Price Target to $36

Olema Oncology Reports Second Quarter 2026 Financial and Operating Results

Olema Pharmaceuticals Q2 EPS $(0.61) Misses $(0.55) Estimate

Olema Oncology Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Does Olema Pharmaceuticals' (OLMA) Broad Russell Growth Inclusion Reveal a Turning Point in Its Investor Story?

How Olema Pharmaceuticals (OLMA) Is Adding Pipeline Depth Behind Its Palazestrant Breast Cancer Bet

Olema Pharmaceuticals, Inc. (OLMA) Presents at Goldman Sachs 47th Annual Global Healthcare Conference 2026 Transcript

Olema Oncology Announces Clinical Trial Collaboration and Supply Agreement with Bayer to Evaluate OP-3136 in Combination with NUBEQA® (darolutamide) in Metastatic Castration-Resistant Prostate Cancer

Olema Pharma Announces Clinical Trial Collaboration And Supply Agreement With Bayer To Evaluate OP-3136 In Combination With NUBEQA In Patients With mCRPC